2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1619

Early Vascular Ageing as a Predictor of Future Cardiovascular Events and Mortality in Systemic Lupus Erythematosus Patients: A Prospective Cohort Study
Abstract Number: 1620

T-cell Exhaustion in Prolonged Remission SLE Patients
Abstract Number: 1621

The Impact of Disease Activity and Related Factors on Cognitive Dysfunction in SLE
Abstract Number: 1622

Cognitive Impairments in SLE Negatively Related to Participation and Quality of Life: A Systematic Review
Abstract Number: 1623

Mortality in a SLE Inception Cohort of Hispanic Patients
Abstract Number: 1624

Progression and Factors Associated with Damage Accrual in a SLE Inception Cohort of Hispanic Patients
Abstract Number: 1625

Severe Infection Prior to Diagnosis of Systemic Lupus Erythematosus (SLE) Is Associated with Disease-Specific Attributes and Long-Term Comorbidities
Abstract Number: 1626

Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus
Abstract Number: 1627

Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure
Abstract Number: 1628

Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom
Abstract Number: 1629

Significance of Abnormal Nailfold Videocapillarscopy Among Patients with Raynaud’s Phenomenon And/or Suspected Connective Tissue Disease: A Cross-Sectional Single-Center US Experience
Abstract Number: 1630

Contribution of Chest Wall Muscle Atrophy to Decline of Forced Vital Capacity in Patients with Systemic Sclerosis-associated Interstitial Lung Disease
Abstract Number: 1631

Assessment of the Repeatability and Convergent Validity with Dermal Collagen of High Frequency Ultrasound in Systemic Sclerosis
Abstract Number: 1632

Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis
Abstract Number: 1633

Relationship Between YKL-40, VEGF, and IL-5 in Borderline mPAP and Pulmonary Hypertension in Systemic Sclerosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].